Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - Therapure Biopharma

Drug Profile

Immune globulin - Therapure Biopharma

Alternative Names: 10% intravenous immunoglobulin - Therapure Biopharma; 10% IVIG - Therapure Biopharma; Human Immunoglobulin - Therapure Biopharma; Intravenous immunoglobulin - Therapure Biopharma; PlasmaCap IG

Latest Information Update: 03 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therapure Biopharma
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Immunodeficiency disorders

Most Recent Events

  • 22 Feb 2019 Interim adverse events data from a phase III trial in Immunodeficiency disorders presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-WAO)
  • 25 Sep 2018 Evolve Biologics plans to submit a Biologics License Application (BLA) to the USFDA for Immunodeficiency disorders
  • 05 Sep 2017 Phase-III clinical trials in Immunodeficiency disorders in Canada (IV) (NCT03238079)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top